Amarin EXPECTS FDA Approval and 3 Stock Analyses Not to be Missed
IAC/InterActiveCorp. (NASDAQ:IACI), according to Benchmark Co. has momentum in search and Match is sustainable. The firm maintains a Buy rating on the stock.
Don’t Miss: Cisco Gets Thumbs-Up For This HUGE BUY.
Triumph Group, Inc. (NYSE:TGI) has been added to the U.S. 1 List at BofA/Merrill.
Cardinal Health, Inc. (NYSE:CAH): UBS thinks Cardinal Health will re-up its contract with Express Scripts/Medco and will make an announcement in coming weeks.
Amarin Corporation plc‘s (NASDAQ:AMRN) AMR101 is expected by Roth Capital to get full FDA approval for the MARINE population, and to be bought out or to enter into a major international partnership. Shares of Amarin are Buy rated with a $21 price target.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.